| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Orion Oyj (HE: ORNBV)
ORNBV Technical Analysis
5
| As on 24th Apr 2025 ORNBV SHARE Price closed @ 53.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 39.90 & Strong Buy for SHORT-TERM with Stoploss of 38.78 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ORNBVSHARE Price
| Open | 51.55 | Change | Price | % |
| High | 54.05 | 1 Day | 3.40 | 6.78 |
| Low | 51.50 | 1 Week | 5.61 | 11.70 |
| Close | 53.55 | 1 Month | 0.49 | 0.92 |
| Volume | 359279 | 1 Year | 16.86 | 45.95 |
| 52 Week High 57.70 | 52 Week Low 32.27 | ||||
HE Finland Most Active Stocks
| NOKIA | 4.25 | -9.38% |
| SAMPO | 8.68 | -3.66% |
| NDA-FI | 11.68 | 0.17% |
| NESTE | 8.07 | 0.88% |
| UPM | 23.40 | 0.60% |
| STERV | 7.95 | 0.38% |
| MOCORP | 10.22 | -2.29% |
| WRT1V | 15.43 | 0.52% |
| FORTUM | 13.56 | 0.30% |
| DIGIGR | 0.04 | 33.33% |
HE Finland Top Gainers Stocks
HE Finland Top Losers Stocks
| ORNBV Daily Charts |
ORNBV Intraday Charts |
Whats New @ Bazaartrend |
ORNBV Free Analysis |
|
|
ORNBV Important Levels Intraday
| RESISTANCE | 58.46 |
| RESISTANCE | 56.89 |
| RESISTANCE | 55.91 |
| RESISTANCE | 54.94 |
| SUPPORT | 52.16 |
| SUPPORT | 51.19 |
| SUPPORT | 50.21 |
| SUPPORT | 48.64 |
ORNBV Forecast April 2025
| 4th UP Forecast | 71.99 |
| 3rd UP Forecast | 66.08 |
| 2nd UP Forecast | 62.42 |
| 1st UP Forecast | 58.77 |
| 1st DOWN Forecast | 48.33 |
| 2nd DOWN Forecast | 44.68 |
| 3rd DOWN Forecast | 41.02 |
| 4th DOWN Forecast | 35.11 |
ORNBV Weekly Forecast
| 4th UP Forecast | 56.48 |
| 3rd UP Forecast | 55.54 |
| 2nd UP Forecast | 54.96 |
| 1st UP Forecast | 54.38 |
| 1st DOWN Forecast | 52.72 |
| 2nd DOWN Forecast | 52.14 |
| 3rd DOWN Forecast | 51.56 |
| 4th DOWN Forecast | 50.62 |
ORNBV Forecast2025
| 4th UP Forecast | 103.34 |
| 3rd UP Forecast | 87.37 |
| 2nd UP Forecast | 77.5 |
| 1st UP Forecast | 67.63 |
| 1st DOWN Forecast | 39.47 |
| 2nd DOWN Forecast | 29.6 |
| 3rd DOWN Forecast | 19.73 |
| 4th DOWN Forecast | 3.76 |
Orion Oyj ( HE Finland Symbol : ORNBV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ORNBV Business Profile
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland. Address: Orionintie 1A, Espoo, Finland, 02200
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service